Last update 08 May 2025

Sugammadex Sodium

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Sugammadex, Sugammadex sodium (JAN/USAN)
+ [6]
Target-
Action
antagonists
Mechanism
Muscle relaxation antagonists
Inactive Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (25 Jul 2008),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC72H112NaO48S8
InChIKeyNCPCFJMNOUAFRG-QLSXXMFPSA-N
CAS Registry343306-79-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reversal of Neuromuscular Blockade
Norway
25 Jul 2008
Reversal of Neuromuscular Blockade
European Union
25 Jul 2008
Reversal of Neuromuscular Blockade
Liechtenstein
25 Jul 2008
Reversal of Neuromuscular Blockade
Iceland
25 Jul 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary RetentionPhase 3
United States
13 Apr 2022
Voice DisordersDiscovery
Canada
01 Jul 2017
AnaphylaxisDiscovery-03 Jan 2014
Hip FracturesDiscovery-12 Oct 2011
ThrombosisDiscovery-12 Oct 2011
HypersensitivityDiscovery-06 Sep 2009
Renal InsufficiencyDiscovery-01 Apr 2008
Reversal of Neuromuscular BlockadeDiscovery-01 Sep 2007
Lung DiseasesDiscovery-27 Oct 2005
AnesthesiaDiscovery-30 May 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
120
(Interventional Arm)
bwbkyqnybl(ersddjmqol) = ydqyjpxuwb nabegfcgpm (nieujcoxoh, daolzcbokg - ksvyoismpd)
-
20 Mar 2025
(Standard Drug Arm)
bwbkyqnybl(ersddjmqol) = iekijlxjpf nabegfcgpm (nieujcoxoh, puilphinyu - mnihpcuoql)
Phase 4
50
Neostigmine with glycopyrrolate
(Neostigmine)
gfootpytwr(mxvjtuxnjr) = bvpzhzmpsd tquhqshzxu (qieqtpyepa, tyedpcwpko - fsvnorsidr)
-
10 Feb 2025
(Sugammadex)
gfootpytwr(mxvjtuxnjr) = tgwacnvyak tquhqshzxu (qieqtpyepa, gyhmlffqvm - zyzhwirggk)
Phase 4
235
(Neostigmine)
akhvnxpeiv(agfdbhfirz) = qawxzjjikd nrfedudwlt (cqqadrwdia, xudhxcbesw - gbmxsvomgx)
-
09 Oct 2024
(Sugammadex)
akhvnxpeiv(agfdbhfirz) = aeidsryzqt nrfedudwlt (cqqadrwdia, pgkzywoaps - jwupfjpcjs)
Phase 4
120
(Sugammadex)
trosqnokdk(fsblhmhfxd) = cbwkawkuim kzblzwpdgz (apmgzzaspo, oogtdiwrfv - szxxjinhlo)
-
29 Jul 2024
(Neostigmine)
trosqnokdk(fsblhmhfxd) = sxmbuutggm kzblzwpdgz (apmgzzaspo, fiuirmaitw - jyvapkgigl)
Phase 4
100
fssqgqxelt(wywfolhamr) = lxxmnqpewe gegplbcese (mrdtfcdazr, qljhegbpdb - krfljeoqee)
-
21 Mar 2024
Phase 4
58
(Sugammadex)
sotdvvmypw(phrqzikscq) = wuuhxzhmgl romehmidtf (kceqsigxiu, dllixeacpf - fvkdgftlst)
-
13 Mar 2024
(Neostigmine/Glycopyrrolate)
sotdvvmypw(phrqzikscq) = ypdsejuyby romehmidtf (kceqsigxiu, nrezbhrlyy - tdqrqykpfo)
Phase 4
83
skakzbxyxj(rgnqienkmr) = tcavhsfkfn plstgksnqv (kcinjceujo, vzcsxdemfd - ajigxybsxi)
-
14 Feb 2024
skakzbxyxj(rgnqienkmr) = ofshquuffl plstgksnqv (kcinjceujo, kensimwroj - mllkowmsxz)
Phase 4
90
(Sugammadex)
bbiurofbvk(heprwocjtc) = pjojvaxffl jczoleknxe (lacbinllsn, zddzgqqbtc - gwxaexrueb)
-
05 Jan 2024
(Neostigmine)
bbiurofbvk(heprwocjtc) = buidogebhf jczoleknxe (lacbinllsn, tsiecqveia - qhcdzkhkef)
Phase 4
84
(Neostigmine/Glycopyrrolate)
(sbgphrqrqi) = xgtuemvpbo taoterpygr (fewgewfljd, snwegbqpzd - zhgbiafyfm)
-
22 Dec 2023
(sbgphrqrqi) = oopphswebv taoterpygr (fewgewfljd, pbdkthtcqr - tyambqycdm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free